Trial Profile
Efficacy, Safety, and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster; Varicella zoster virus infections
- Focus Registrational; Therapeutic Use
- Acronyms ZOE-50; ZOSTER-006
- Sponsors GlaxoSmithKline; GSK
- 05 Oct 2021 Results of a post hoc analysis published in the Journal of Infectious Diseases
- 25 Oct 2020 Results assessing vaccine efficacy (VE) of the adjuvanted recombinant zoster vaccine from NCT01165177, NCT01165229 and NCT01610414 presented at the IDWeek 2020.
- 05 May 2019 this trial is discontinued in france.